TESARO, Inc. (NASDAQ:TSRO) Given Average Rating of “Buy” by Analysts
Shares of TESARO, Inc. (NASDAQ:TSRO) have received an average recommendation of “Buy” from the twenty-six brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation, fourteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $176.67.
A number of equities analysts recently weighed in on the company. Janney Montgomery Scott set a $139.00 price target on TESARO and gave the stock a “hold” rating in a research note on Saturday, June 10th. Zacks Investment Research raised TESARO from a “sell” rating to a “hold” rating in a research note on Friday, March 31st. Cowen and Company set a $145.00 price target on TESARO and gave the stock a “hold” rating in a research note on Saturday, June 10th. Gabelli assumed coverage on TESARO in a research note on Friday. They issued a “buy” rating and a $175.00 price target on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $164.00 price target (down previously from $200.00) on shares of TESARO in a research note on Wednesday, March 15th.
In related news, VP Edward C. English sold 8,500 shares of the business’s stock in a transaction that occurred on Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total value of $1,178,525.00. Following the completion of the sale, the vice president now directly owns 5,396 shares in the company, valued at approximately $748,155.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 34.60% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new position in shares of TESARO during the fourth quarter valued at approximately $3,292,000. Dimensional Fund Advisors LP increased its position in shares of TESARO by 2.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 90,321 shares of the biopharmaceutical company’s stock valued at $12,146,000 after buying an additional 1,748 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of TESARO during the fourth quarter valued at approximately $502,000. Metropolitan Life Insurance Co. NY increased its position in shares of TESARO by 5.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 19,749 shares of the biopharmaceutical company’s stock valued at $2,656,000 after buying an additional 1,043 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in shares of TESARO by 18.2% in the fourth quarter. AQR Capital Management LLC now owns 46,697 shares of the biopharmaceutical company’s stock valued at $6,279,000 after buying an additional 7,174 shares in the last quarter.
Shares of TESARO (NASDAQ:TSRO) traded down 0.17% during midday trading on Tuesday, reaching $132.42. 614,024 shares of the company were exchanged. TESARO has a 52-week low of $83.26 and a 52-week high of $192.94. The firm’s 50 day moving average is $146.21 and its 200-day moving average is $151.73. The company’s market capitalization is $7.13 billion.
TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.26) by $0.29. The company had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $3.84 million. TESARO had a negative return on equity of 96.49% and a negative net margin of 910.35%. The company’s revenue for the quarter was up 909.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.22) EPS. On average, equities analysts forecast that TESARO will post ($8.74) earnings per share for the current fiscal year.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.